Your request to link to rcsb for Carbonic anhydrase 2


  • 1CAH: structure of cobalt carbonic anhydrase complexed with bicarbonate (10.1016/0022-2836(92)90327-G )
  • 1CAI: structural analysis of the zinc hydroxide-thr 199-glu 106 hydrogen bonding network in human carbonic anhydrase ii (10.1002/PROT.340170112 )
  • 1CAJ: structural analysis of the zinc hydroxide-thr 199-glu 106 hydrogen bonding network in human carbonic anhydrase ii (10.1002/PROT.340170112 )
  • 1CAK: structural analysis of the zinc hydroxide-thr 199-glu 106 hydrogen bonding network in human carbonic anhydrase ii (10.1002/PROT.340170112 )
  • 1CAL: structural analysis of the zinc hydroxide-thr 199-glu 106 hydrogen bonding network in human carbonic anhydrase ii (10.1002/PROT.340170112 )
  • 1CAM: structural analysis of the zinc hydroxide-thr 199-glu 106 hydrogen bonding network in human carbonic anhydrase ii (10.1002/PROT.340170112 )
  • 1CAN: crystallographic studies of the binding of protonated and unprotonated inhibitors to carbonic anhydrase using hydrogen sulphide and nitrate anions (10.1111/J.1432-1033.1992.TB17490.X )
  • 1CAO: crystallographic studies of the binding of protonated and unprotonated inhibitors to carbonic anhydrase using hydrogen sulphide and nitrate anions (10.1111/J.1432-1033.1992.TB17490.X )
  • 1CAY: wild-type and e106q mutant carbonic anhydrase complexed with acetate (10.1107/S0907444993009667 )
  • 1CAZ: wild-type and e106q mutant carbonic anhydrase complexed with acetate (10.1107/S0907444993009667 )
  • 1CCS: structure-assisted redesign of a protein-zinc binding site with femtomolar affinity (10.1073/PNAS.92.11.5017 )
  • 1CCT: structure-assisted redesign of a protein-zinc binding site with femtomolar affinity (10.1073/PNAS.92.11.5017 )
  • 1CCU: structure-assisted redesign of a protein-zinc binding site with femtomolar affinity (10.1073/PNAS.92.11.5017 )
  • 1CIL: the positions of his-64 and a bound water in human carbonic anhydrase ii upon binding three structurally related inhibitors
  • 1CIM: the positions of his-64 and a bound water in human carbonic anhydrase ii upon binding three structurally related inhibitors
  • 1CIN: the positions of his-64 and a bound water in human carbonic anhydrase ii upon binding three structurally related inhibitors
  • 1CNB: compensatory plastic effects in the redesign of protein-zinc binding sites (10.1021/BI00255A004 )
  • 1CNC: compensatory plastic effects in the redesign of protein-zinc binding sites (10.1021/BI00255A004 )
  • 1CNG: x-ray crystallographic studies of engineered hydrogen bond networks in a protein-zinc binding site
  • 1CNH: x-ray crystallographic studies of engineered hydrogen bond networks in a protein-zinc binding site
  • 1CNI: x-ray crystallographic studies of engineered hydrogen bond networks in a protein-zinc binding site
  • 1CNJ: x-ray crystallographic studies of engineered hydrogen bond networks in a protein-zinc binding site
  • 1CNK: x-ray crystallographic studies of engineered hydrogen bond networks in a protein-zinc binding site
  • 1CNW: secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase ii influence binding constants (10.1021/JM00013A004 )
  • 1CNX: secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase ii influence binding constants (10.1021/JM00013A004 )
  • 1CNY: secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase ii influence binding constants (10.1021/JM00013A004 )
  • 1CRA: the complex between human carbonic anhydrase ii and the aromatic inhibitor 1,2,4-triazole (10.1006/JMBI.1993.1365 )
  • 1CVA: structural and functional importance of a conserved hydrogen bond network in human carbonic anhydrase ii
  • 1CVB: structural and functional importance of a conserved hydrogen bond network in human carbonic anhydrase ii
  • 1CVC: redesigning the zinc binding site of human carbonic anhydrase ii: structure of a his2asp-zn2+ metal coordination polyhedron
  • 1CVD: structural consequences of redesigning a protein-zinc binding site (10.1021/BI00255A004 )
  • 1CVE: structural consequences of redesigning a protein-zinc binding site (10.1021/BI00255A004 )
  • 1CVF: structural consequences of redesigning a protein-zinc binding site (10.1021/BI00255A004 )
  • 1CVH: structural consequences of redesigning a protein-zinc binding site (10.1021/BI00255A004 )
  • 1DCA: structure of an engineered metal binding site in human carbonic anhydrase ii reveals the architecture of a regulatory cysteine switch (10.1021/BI00089A005 )
  • 1DCB: structure of an engineered metal binding site in human carbonic anhydrase ii reveals the architecture of a regulatory cysteine switch (10.1021/BI00089A005 )
  • 1EOU: crystal structure of human carbonic anhydrase ii complexed with an anticonvulsant sugar sulfamate (10.1042/0264-6021:3610437 )
  • 1F2W: the mechanism of cyanamide hydration catalyzed by carbonic anhydrase ii revealed by cryogenic x-ray diffraction (10.1021/BI000937C )
  • 1FQL: x-ray crystal structure of zinc-bound f95m/w97v carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1FQM: x-ray crystal structure of zinc-bound f93i/f95m/w97v carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1FQN: x-ray crystal structure of metal-free f93i/f95m/w97v carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1FQR: x-ray crystal structure of cobalt-bound f93i/f95m/w97v carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1FR4: x-ray crystal structure of copper-bound f93i/f95m/w97v carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1FR7: x-ray crystal structure of zinc-bound f93s/f95l/w97m carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1FSN: x-ray crystal structure of metal-free f93s/f95l/w97m carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1FSQ: x-ray crystal structure of cobalt-bound f93s/f95l/w97m carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1FSR: x-ray crystal structure of copper-bound f93s/f95l/w97m carbonic anhydrase (caii) variant (10.1021/BI001649J )
  • 1G0E: site-specific mutant (his64 replaced with ala) of human carbonic anhydrase ii complexed with 4-methylimidazole (10.1021/BI002295Z )
  • 1G0F: site-specific mutant (his64 replaced with ala) of human carbonic anhydrase ii (10.1021/BI002295Z )
  • 1G1D: carbonic anhydrase ii complexed with 4-(aminosulfonyl)-n-[(2- fluorophenyl)methyl]-benzamide (10.1021/JA002627N )
  • 1G3Z: carbonic anhydrase ii (f131v) (10.1021/JA002627N )
  • 1G45: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2- fluorophenyl)methyl]-benzamide (10.1021/JA002627N )
  • 1G46: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 3-difluorophenyl)methyl]-benzamide (10.1021/JA002627N )
  • 1G48: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 6-difluorophenyl)methyl]-benzamide (10.1021/JA002627N )
  • 1G4J: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 3,4,5,6-pentafluorophenyl)methyl]-benzamide (10.1021/JA002627N )
  • 1G4O: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n- phenylmethylbenzamide (10.1021/JA002627N )
  • 1G52: carbonic anhydrase ii complexed with 4-(aminosulfonyl)-n-[(2,3- difluorophenyl)methyl]-benzamide (10.1021/JA002627N )
  • 1G53: carbonic anhydrase ii complexed with 4-(aminosulfonyl)-n-[(2,6- difluorophenyl)methyl]-benzamide (10.1021/JA002627N )
  • 1G54: carbonic anhydrase ii complexed with 4-(aminosulfonyl)-n-[(2,3,4,5,6- pentafluorophenyl)methyl]-benzamide (10.1021/JA002627N )
  • 1G6V: complex of the camelid heavy-chain antibody fragment cab- ca05 with bovine carbonic anhydrase (10.1074/JBC.M102107200 )
  • 1H4N: h94n carbonic anhydrase ii complexed with tris (10.1021/BI971296X )
  • 1H9N: h119n carbonic anhydrase ii (10.1021/BI971296X )
  • 1H9Q: h119q carbonic anhydrase ii (10.1021/BI971296X )
  • 1HCA: unexpected ph-dependent conformation of his-64, the proton shuttle of carbonic anhydrase ii.
  • 1HEA: carbonic anhydrase ii (carbonate dehydratase) (hca ii) (e.c.4.2.1.1) mutant with leu 198 replaced by arg (l198r) (10.1021/BI00068A005 )
  • 1HEB: structural consequences of hydrophilic amino-acid substitutions in the hydrophobic pocket of human carbonic anhydrase ii (10.1021/BI00068A005 )
  • 1HEC: structural consequences of hydrophilic amino-acid substitutions in the hydrophobic pocket of human carbonic anhydrase ii (10.1021/BI00068A005 )
  • 1HED: structural consequences of hydrophilic amino-acid substitutions in the hydrophobic pocket of human carbonic anhydrase ii (10.1021/BI00068A005 )
  • 1HVA: engineering the zinc binding site of human carbonic anhydrase ii: structure of the his-94-> cys apoenzyme in a new crystalline form (10.1021/BI00057A015 )
  • 1I8Z: carbonic anhydrase ii complexed with al-6629 2h-thieno[3,2-e]-1,2- thiazine-6-sulfonamide, 2-(3-methoxyphenyl)-3-(4-morpholinyl)-, 1,1- dioxide (10.1021/JM010163D )
  • 1I90: carbonic anhydrase ii complexed with al-8520 2h-thieno[3,2-e]-1,2- thiazine-6-sulfonamide, 4-amino-3,4-dihydro-2-(3-methoxypropyl)-, 1, 1-dioxide, (r) (10.1021/JM010163D )
  • 1I91: carbonic anhydrase ii complexed with al-6619 2h-thieno[3,2-e]-1,2- thiazine-6-sulfonamide, 2-(3-hydroxyphenyl)-3-(4-morpholinyl)-, 1,1- dioxide (10.1021/JM010163D )
  • 1I9L: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(4- fluorophenyl)methyl]-benzamide (10.1021/JA011034P )
  • 1I9M: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 4-difluorophenyl)methyl]-benzamide (10.1021/JA011034P )
  • 1I9N: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 5-difluorophenyl)methyl]-benzamide (10.1021/JA011034P )
  • 1I9O: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 3,4-trifluorophenyl)methyl]-benzamide (10.1021/JA011034P )
  • 1I9P: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 4,6-trifluorophenyl)methyl]-benzamide (10.1021/JA011034P )
  • 1I9Q: carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(3, 4,5-trifluorophenyl)methyl]-benzamide (10.1021/JA011034P )
  • 1IF4: carbonic anhydrase ii complexed with 4-fluorobenzenesulfonamide
  • 1IF5: carbonic anhydrase ii complexed with 2,6-difluorobenzenesulfonamide
  • 1IF6: carbonic anhydrase ii complexed with 3,5-difluorobenzenesulfonamide
  • 1IF7: carbonic anhydrase ii complexed with (r)-n-(3-indol-1-yl-2-methyl- propyl)-4-sulfamoyl-benzamide (10.1073/PNAS.032673399 )
  • 1IF8: carbonic anhydrase ii complexed with (s)-n-(3-indol-1-yl-2-methyl- propyl)-4-sulfamoyl-benzamide (10.1073/PNAS.032673399 )
  • 1IF9: carbonic anhydrase ii complexed with n-[2-(1h-indol-5-yl)-butyl]-4- sulfamoyl-benzamide (10.1073/PNAS.032673399 )
  • 1KWQ: human carbonic anhydrase ii complexed with inhibitor 2000-07 (10.1021/JM011112J )
  • 1KWR: human carbonic anhydrase ii complexed with inhibitor 0134-36 (10.1021/JM011112J )
  • 1LG5: crystal structure analysis of the hca ii mutant t199p in complex with beta-mercaptoethanol (10.1021/BI020053O )
  • 1LG6: crystal structure analysis of hca ii mutant t199p in complex with thiocyanate (10.1021/BI020053O )
  • 1LGD: crystal structure analysis of hca ii mutant t199p in complex with bicarbonate (10.1021/BI020053O )
  • 1LUG: full matrix error analysis of carbonic anhydrase (10.1107/S0907444910006554 )
  • 1LZV: site-specific mutant (tyr7 replaced with his) of human carbonic anhydrase ii (10.1074/JBC.M205791200 )
  • 1MOO: site specific mutant (h64a) of human carbonic anhydrase ii at high resolution (10.1107/S0907444902019455 )
  • 1MUA: structure and energetics of a non-proline cis-peptidyl linkage in an engineered protein (10.1021/BI00092A003 )
  • 1OKL: carbonic anhydrase ii complex with the 1okl inhibitor 5- dimethylamino-naphthalene-1-sulfonamide
  • 1OKM: carbonic anhydrase ii complex with the 1okm inhibitor 4- sulfonamide-[1-(4-aminobutane)]benzamide
  • 1OKN: carbonic anhydrase ii complex with the 1okn inhibitor 4- sulfonamide-[1-(4-n-(5-fluorescein thiourea)butane)]
  • 1OQ5: carbonic anhydrase ii in complex with nanomolar inhibitor (10.1021/JM030912M )
  • 1RAY: the structure of human carbonic anhydrase ii in complex with bromide and azide (10.1016/0014-5793(93)81565-H )
  • 1RAZ: the structure of human carbonic anhydrase ii in complex with bromide and azide (10.1016/0014-5793(93)81565-H )
  • 1RZA: x-ray analysis of metal substituted human carbonic anhydrase ii derivatives (10.1107/S0907444993008790 )
  • 1RZB: x-ray analysis of metal substituted human carbonic anhydrase ii derivatives (10.1107/S0907444993008790 )
  • 1RZC: x-ray analysis of metal substituted human carbonic anhydrase ii derivatives (10.1107/S0907444993008790 )
  • 1RZD: x-ray analysis of metal substituted human carbonic anhydrase ii derivatives (10.1107/S0907444993008790 )
  • 1RZE: x-ray analysis of metal substituted human carbonic anhydrase ii derivatives (10.1107/S0907444993008790 )
  • 1T9N: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TB0: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TBT: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TE3: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TEQ: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TEU: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TG3: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TG9: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TH9: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1THK: effect of shuttle location and ph environment on h+ transfer in human carbonic anhydrase ii (10.1021/BI0480279 )
  • 1TTM: human carbonic anhydrase ii complexed with 667-coumate (10.1042/BJ20041037 )
  • 1UGA: human carbonic anhydrase ii[hcaii] (e.c.4.2.1.1) mutant with ala 65 replaced by phe (a65f) (10.1021/BI9617872 )
  • 1UGB: human carbonic anhydrase ii[hcaii] (e.c.4.2.1.1) mutant with ala 65 replaced by gly (a65g) (10.1021/BI9617872 )
  • 1UGC: human carbonic anhydrase ii [hcaii] (e.c.4.2.1.1) mutant with ala 65 replaced by his (a65h) (10.1021/BI9617872 )
  • 1UGD: human carbonic anhydrase ii[hcaii] (e.c.4.2.1.1) mutant with ala 65 replaced by ser (a65s) (10.1021/BI9617872 )
  • 1UGE: human carbonic anhydrase ii [hcaii] (e.c.4.2.1.1) mutant with ala 65 replaced by leu (a65l) (10.1021/BI9617872 )
  • 1UGF: human carbonic anhydrase ii [hcaii] (e.c.4.2.1.1) mutant with ala 65 replaced by thr (a65t) (10.1021/BI9617872 )
  • 1UGG: human carbonic anhydrase ii[hcaii] (e.c.4.2.1.1) mutant with ala 65 replaced by ser (a65s)-orthorhombic form (10.1021/BI9617872 )
  • 1XEG: crystal structure of human carbonic anhydrase ii complexed with an acetate ion (10.1107/S1744309108002078 )
  • 1XEV: crystal structure of human carbonic anhydrase ii in a new crystal form
  • 1XPZ: structure of human carbonic anhydrase ii with 4-[4-o- sulfamoylbenzyl)(4-cyanophenyl)amino]-4h-[1,2,4]-triazole (10.1021/BI047692E )
  • 1XQ0: structure of human carbonic anhydrase ii with 4-[(3-bromo-4- o-sulfamoylbenzyl)(4-cyanophenyl)amino]-4h-[1,2,4]-triazole (10.1021/BI047692E )
  • 1YDA: structural basis of inhibitor affinity to variants of human carbonic anhydrase ii (10.1021/BI00012A016 )
  • 1YDB: structural basis of inhibitor affinity to variants of human carbonic anhydrase ii (10.1021/BI00012A016 )
  • 1YDC: structural basis of inhibitor affinity to variants of human carbonic anhydrase ii (10.1021/BI00012A016 )
  • 1YDD: structural basis of inhibitor affinity to variants of human carbonic anhydrase ii (10.1021/BI00012A016 )
  • 1YO0: proton transfer from his200 in human carbonic anhydrase ii (10.1002/PROT.20615 )
  • 1YO1: proton transfer from his200 in human carbonic anhydrase ii (10.1002/PROT.20615 )
  • 1YO2: proton transfer from his200 in human carbonic anhydrase ii (10.1002/PROT.20615 )
  • 1Z9Y: carbonic anhydrase ii in complex with furosemide as sulfonamide inhibitor
  • 1ZE8: carbonic anhydrase ii in complex with a membrane-impermeant sulfonamide inhibitor (10.1021/JM050333C )
  • 1ZFK: carbonic anhydrase ii in complex with n-4-sulfonamidphenyl-n'-4- methylbenzosulfonylurease as sulfonamide inhibitor
  • 1ZFQ: carbonic anhydrase ii in complex with ethoxzolamidphenole as sulfonamide inhibitor
  • 1ZGE: carbonic anhydrase ii in complex with p-sulfonamido-o,o'- dichloroaniline as sulfonamide inhibitor
  • 1ZGF: carbonic anhydrase ii in complex with trichloromethiazide as sulfonamide inhibitor
  • 1ZH9: carbonic anhydrase ii in complex with n-4-methyl-1-piperazinyl-n'-(p- sulfonamide)phenylthiourea as sulfonamide inhibitor
  • 1ZSA: carbonic anhydrase ii mutant e117q, apo form (10.1021/BI9526692 )
  • 1ZSB: carbonic anhydrase ii mutant e117q, transition state analogue acetazolamide (10.1021/BI9526692 )
  • 1ZSC: carbonic anhydrase ii mutant e117q, holo form (10.1021/BI9526692 )
  • 2ABE: carbonic anhydrase activators: x-ray crystal structure of the adduct of human isozyme ii with l-histidine as a platform for the design of stronger activators (10.1016/J.BMCL.2005.08.069 )
  • 2AW1: carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform ii as compared to the structurally related cyclooxygenase ii "selective" inhibitor celecoxib (10.1016/J.BMCL.2005.09.040 )
  • 2AX2: production and x-ray crystallographic analysis of fully deuterated human carbonic anhydrase ii (10.1107/S1744309105038248 )
  • 2CA2: crystallographic studies of inhibitor binding sites in human carbonic anhydrase ii. a pentacoordinated binding of the scn-ion to the zinc at high p*h (10.1002/PROT.340040407 )
  • 2CBA: structure of native and apo carbonic anhydrase ii and some of its anion-ligand complexes (10.1016/0022-2836(92)90531-N )
  • 2CBB: structure of native and apo carbonic anhydrase ii and some of its anion-ligand complexes (10.1016/0022-2836(92)90531-N )
  • 2CBC: structure of native and apo carbonic anhydrase ii and some of its anion-ligand complexes (10.1016/0022-2836(92)90531-N )
  • 2CBD: structure of native and apo carbonic anhydrase ii and some of its anion-ligand complexes (10.1016/0022-2836(92)90531-N )
  • 2CBE: structure of native and apo carbonic anhydrase ii and some of its anion-ligand complexes (10.1016/0022-2836(92)90531-N )
  • 2EU2: human carbonic anhydrase ii in complex with novel inhibitors (10.1107/S1744309106020446 )
  • 2EU3: human carbonic anhydrase ii in complex with novel inhibitors (10.1107/S1744309106020446 )
  • 2EZ7: carbonic anhydrase activators. activation of isozymes i, ii, iv, va, vii and xiv with l- and d-histidine and crystallographic analysis of their adducts with isoform ii: engineering proton transfer processes within the active site of an enzyme (10.1002/CHEM.200600159 )
  • 2F14: tne crystal structure of the human carbonic anhydrase ii in complex with a fluorescent inhibitor (10.1021/JA061574S )
  • 2FMG: carbonic anhydrase activators. activation of isoforms i, ii, iv, va, vii and xiv with l- and d- phenylalanine and crystallographic analysis of their adducts with isozyme ii: sterospecific recognition within the active site of an enzyme and its consequences for the drug design, structure with l-phenylalanine (10.1021/JM0603320 )
  • 2FMZ: carbonic anhydrase activators. activation of isoforms i, ii, iv, va, vii and xiv with l- and d- phenylalanine, structure with d- phenylalanine. (10.1021/JM0603320 )
  • 2FNK: activation of human carbonic anhydrase ii by exogenous proton donors (10.1529/BIOPHYSJ.106.093203 )
  • 2FNM: activation of human carbonic anhdyrase ii by exogenous proton donors (10.1529/BIOPHYSJ.106.093203 )
  • 2FNN: activation of human carbonic anhydrase ii by exogenous proton donors (10.1529/BIOPHYSJ.106.093203 )
  • 2FOQ: human carbonic anhydrase ii complexed with two-prong inhibitors (10.1021/JA057257N )
  • 2FOS: human carbonic anhydrase ii complexed with two-prong inhibitors (10.1021/JA057257N )
  • 2FOU: human carbonic anhydrase ii complexed with two-prong inhibitors (10.1021/JA057257N )
  • 2FOV: human carbonic anhydrase ii complexed with two-prong inhibitors (10.1021/JA057257N )
  • 2GD8: crystal structure analysis of the human carbonic anhydrase ii in complex with a 2-substituted estradiol bis-sulfamate (10.1021/JM060705X )
  • 2GEH: n-hydroxyurea, a versatile zinc binding function in the design of metalloenzyme inhibitors (10.1016/J.BMCL.2006.05.068 )
  • 2H15: carbonic anhydrase inhibitors: clashing with ala65 as a means of designing isozyme-selective inhibitors that show low affinity for the ubiquitous isozyme ii (10.1021/JM060807N )
  • 2H4N: h94n carbonic anhydrase ii complexed with acetazolamide (10.1021/BI971296X )
  • 2HD6: crystal structure of the human carbonic anhydrase ii in complex with a hypoxia-activatable sulfonamide. (10.1021/JM060531J )
  • 2HKK: carbonic anhydrase activators: solution and x-ray crystallography for the interaction of andrenaline with various carbonic anhydrase isoforms (10.1016/J.BMCL.2006.11.027 )
  • 2HL4: crystal structure analysis of human carbonic anhydrase ii in complex with a benzenesulfonamide derivative (10.1016/J.BMCL.2006.12.099 )
  • 2HNC: crystal structure of the human carbonic anhydrase ii in complex with the 5-amino-1,3,4-thiadiazole-2-sulfonamide inhibitor. (10.1016/J.BMCL.2006.09.022 )
  • 2HOC: crystal structure of the human carbonic anhydrase ii in complex with the 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole- 2-sulfonamide inhibitor (10.1016/J.BMCL.2006.09.022 )
  • 2ILI: refine atomic structure of human carbonic anhydrase ii (10.1021/BI062066Y )
  • 2NNG: structure of inhibitor binding to carbonic anhydrase ii (10.1021/JA068359W )
  • 2NNO: structure of inhibitor binding to carbonic anhydrase ii (10.1021/JA068359W )
  • 2NNS: structure of inhibitor binding to carbonic anhydrase ii (10.1021/JA068359W )
  • 2NNV: structure of inhibitor binding to carbonic anhydrase ii (10.1021/JA068359W )
  • 2NWO: structural and kinetic effect of hydrophobic mutations in the active site of human carbonic anhydrase ii (10.1021/BI602620K )
  • 2NWP: structural and kinetic effects of hydrophobic mutations in the active site of human carbonic anhydrase ii (10.1021/BI602620K )
  • 2NWY: structural and kinetic effects of hydrophobic mutations on the active site of human carbonic anhydrase ii (10.1021/BI602620K )
  • 2NWZ: structural and kinetic effects of hydrophobic mutations on the active site of human carbonic anhydrase ii (10.1021/BI602620K )
  • 2NXR: structural effects of hydrophobic mutations on the active site of human carbonic anhydrase ii (10.1021/BI602620K )
  • 2NXS: structural and kinetic effects of hydrophobic mutations in the active site of human carbonic anhydrase ii (10.1021/BI602620K )
  • 2NXT: structural and kinetic effects of hydrophobic mutations in the active site of human carbonic anhydrase ii (10.1021/BI602620K )
  • 2O4Z: crystal structure of the carbonic anhydrase ii complexed with hydroxysulfamide inhibitor (10.1016/J.BMCL.2007.02.068 )
  • 2OSF: inhibition of carbonic anhydrase ii by thioxolone: a mechanistic and structural study (10.1021/BI702385K )
  • 2OSM: inhibition of carbonic anhydrase ii by thioxolone: a mechanistic and structural study (10.1021/BI702385K )
  • 2POU: the crystal structure of the human carbonic anhydrase ii in complex with 4,5-dichloro-benzene-1,3-disulfonamide (10.1016/J.BMCL.2007.05.045 )
  • 2POV: the crystal structure of the human carbonic anhydrase ii in complex with 4-amino-6-chloro-benzene-1,3-disulfonamide (10.1016/J.BMCL.2007.05.045 )
  • 2POW: the crystal structure of the human carbonic anhydrase ii in complex with 4-amino-6-trifluoromethyl-benzene-1,3- disulfonamide (10.1016/J.BMCL.2007.05.045 )
  • 2Q1B: carbonic anhydrase ii in complex with saccharin (10.1002/ANIE.200701189 )
  • 2Q1Q: carbonic anhydrase inhibitors. interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and x-ray crystallographic studies (10.1016/J.BMCL.2007.06.044 )
  • 2Q38: carbonic anhydrase ii in complex with saccharin at 1.95 angstrom (10.1002/ANIE.200701189 )
  • 2QO8: crystal structure of the complex of hcaii with an indane-sulfonamide inhibitor (10.1002/CMDC.200700274 )
  • 2QOA: crystal structure of the complex of hcaii with an indane-sulfonamide inhibitor (10.1002/CMDC.200700274 )
  • 2QP6: the crystal structure of the complex of hcaii with a bioreductive antitumor derivative (10.1021/JM800121C )
  • 2VVA: human carbonic anhydrase in complex with co2 (10.1073/PNAS.0904184106 )
  • 2VVB: human carbonic anhydrase ii in complex with bicarbonate (10.1073/PNAS.0904184106 )
  • 2WD2: a chimeric microtubule disruptor with efficacy on a taxane resistant cell line (10.1039/C002558E )
  • 2WD3: highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template (10.1021/JM901705H )
  • 2WEG: thermodynamic optimisation of carbonic anhydrase fragment inhibitors (10.1002/CMDC.200900386 )
  • 2WEH: thermodynamic optimisation of carbonic anhydrase fragment inhibitors (10.1002/CMDC.200900386 )
  • 2WEJ: thermodynamic optimisation of carbonic anhydrase fragment inhibitors (10.1002/CMDC.200900386 )
  • 2WEO: thermodynamic optimisation of carbonic anhydrase fragment inhibitors (10.1002/CMDC.200900386 )
  • 2X7S: structures of human carbonic anhydrase ii inhibitor complexes reveal a second binding site for steroidal and non-steroidal inhibitors. (10.1021/BI902178W )
  • 2X7T: structures of human carbonic anhydrase ii inhibitor complexes reveal a second binding site for steroidal and non-steroidal inhibitors. (10.1021/BI902178W )
  • 2X7U: structures of human carbonic anhydrase ii inhibitor complexes reveal a second binding site for steroidal and non-steroidal inhibitors. (10.1021/BI902178W )
  • 3B4F: carbonic anhydrase inhibitors. interaction of 2-(hydrazinocarbonyl)-3- phenyl-1h-indole-5-sulfonamide with twelve mammalian isoforms: kinetic and x-ray crystallographic studies (10.1016/J.BMCL.2007.10.110 )
  • 3BET: crystal structure of the human carbonic anhydrase ii in complex with stx 641 at 1.85 angstroms resolution (10.1021/JM701319C )
  • 3BL0: carbonic anhydrase inhibitors. interaction of 2-n,n-dimethylamino-1,3, 4-thiadiazole-5-methanesulfonamide with twelve mammalian isoforms: kinetic and x-ray crystallographic studies (10.1016/J.BMCL.2007.12.022 )
  • 3BL1: carbonic anhydrase inhibitors. sulfonamide diuretics revisited old leads for new applications (10.1016/J.BMCL.2008.03.051 )
  • 3C7P: crystal structure of human carbonic anhydrase ii in complex with stx237 (10.1158/1535-7163.MCT-08-0195 )
  • 3CA2: crystallographic studies of inhibitor binding sites in human carbonic anhydrase ii. a pentacoordinated binding of the scn-ion to the zinc at high p*h (10.1002/PROT.340040407 )
  • 3CAJ: crystal structure of the human carbonic anhydrase ii in complex with ethoxzolamide (10.1016/J.BMCL.2008.03.023 )
  • 3CYU: human carbonic anhydrase ii complexed with cryptophane biosensor and xenon (10.1021/JA802214X )
  • 3D8W: use of a carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3D92: human carbonic anhydrase ii bound with substrate carbon dioxide (10.1074/JBC.M805353200 )
  • 3D93: apo human carbonic anhydrase ii bound with substrate carbon dioxide (10.1074/JBC.M805353200 )
  • 3D9Z: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DAZ: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DBU: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DC3: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DC9: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DCC: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DCS: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DCW: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DD0: use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties (10.1021/BI802035F )
  • 3DD8: carbonic anhydrase inhibitors. interaction of the antitumor sulfamate emd-486019 with twelve mammalian isoforms: kinetic and x-ray crystallographic studies (10.1016/J.BMCL.2008.06.105 )
  • 3DV7: role of hydrophilic residues in proton transfer during catalysis by human carbonic anhydrase ii (n62a) (10.1021/BI801473W )
  • 3DVB: x-ray crystal structure of mutant n62v human carbonic anhydrase ii (10.1021/BI801473W )
  • 3DVC: x-ray crystal structure of mutant n62t of human carbonic anhydrase ii (10.1021/BI801473W )
  • 3DVD: x-ray crystal structure of mutant n62d of human carbonic anhydrase ii (10.1021/BI801473W )
  • 3EFI: carbonic anhydrase activators: kinetic and x-ray crystallographic study for the interaction of d- and l-tryptophan with the mammalian isoforms i-xiv (10.1016/J.BMC.2008.08.043 )
  • 3EFT: crystal structure of the complex between carbonic anhydrase ii and a spin-labeled sulfonamide incorporating tempo moiety (10.1021/JP906593C )
  • 3F4X: carbonic anhydrase inhibitors. comparison of chlorthalidone and indapamide x-ray crystal structures in adducts with isozyme ii: when three water molecules make the difference (10.1021/JM801386N )
  • 3F8E: coumarins are a novel class of suicide carbonic anhydrase inhibitors (10.1021/JA809683V )
  • 3FFP: x ray structure of the complex between carbonic anhydrase ii and lc inhibitors (10.1016/J.BMCL.2009.01.038 )
  • 3GZ0: apo-human carbonic anhydrase ii revisited: implications of the loss of a metal in protein structure, stability and solvent network (10.1021/BI9007512 )
  • 3HFP: crystal structure of teh complex between ca ii and the activator mai
  • 3HKN: human carbonic anhydrase ii in complex with (2,3,4,6-tetra-o-acetyl- beta-d-galactopyranosyl) -(1-4)-1,2,3,6-tetra-o-acetyl-1-thio-beta-d- glucopyranosylsulfonamide (10.1021/JM900914E )
  • 3HKQ: human carbonic anhydrase ii in complex with 1-s-d- galactopyranosylsulfonamide (10.1021/JM900914E )
  • 3HKT: human carbonic anhydrase ii in complex with alpha-d-glucopyranosyl-(1- >4)-1-thio-beta-d-glucopyranosylsulfonamide (10.1021/JM900914E )
  • 3HKU: human carbonic anhydrase ii in complex with topiramate (10.1021/JM900914E )
  • 3HLJ: crystal structure of human carbonic anhydrase isozyme ii with 3- methylthiobenzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonamide (10.3109/14756360903571685 )
  • 3HS4: human carbonic anhydrase ii complexed with acetazolamide (10.1107/S1744309109036665 )
  • 3IBI: the crystal structure of the human carbonic anhydrase ii in complex with an aliphatic sulfamate inhibitor (10.1021/JM900641R )
  • 3IBL: the crystal structure of the human carbonic anhydrase ii in complex with an aliphatic bis-sulfamate inhibitor (10.1021/JM900641R )
  • 3IBN: the crystal structure of the human carbonic anhydrase ii in complex with an aliphatic bis-sulfamate inhibitor (10.1021/JM900641R )
  • 3IBU: the crystal structure of the human carbonic anhydrase ii in complex with an aliphatic sulfamate inhibitor (10.1021/JM900641R )
  • 3IEO: the coumarin-binding site in carbonic anhydrase: the antiepileptic lacosamide as an example (10.1021/JM901524F )
  • 3IGP: structure of inhibitor binding to carbonic anhydrase ii (10.1021/JM9014026 )
  • 3K2F: nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma (10.1016/J.BMCL.2009.10.036 )
  • 3K34: human carbonic anhydrase ii with a sulfonamide inhibitor (10.1107/S0907444910006554 )
  • 3K7K: crystal structure of the complex between carbonic anhydrase ii and anions (10.1016/J.BMCL.2009.11.124 )
  • 3KIG: mutant carbonic anhydrase ii in complex with an azide and an alkyne (10.1002/CHEM.201002437 )
  • 3KKX: neutron structure of human carbonic anhydrase ii (10.1021/BI901995N )
  • 3KNE: carbonic anhydrase ii h64c mutant in complex with an in situ formed triazole (10.1002/CHEM.201002437 )
  • 3KOI: crystal structure of cobalt (iii) human carbonic anhydrase ii at ph 6.0 (10.1016/J.ABB.2010.07.010 )
  • 3KOK: crystal structure of cobalt (ii) human carbonic anhydrase ii at ph 8.5 (10.1016/J.ABB.2010.07.010 )
  • 3KON: crystal structure of cobalt (ii) human carbonic anhydrase ii at ph 11.0 (10.1016/J.ABB.2010.07.010 )
  • 3KS3: high resolution structure of human carbonic anhydrase ii at 0.9 a (10.1021/BI902007B )
  • 3KWA: polyamines inhibit carbonic anhydrases (10.1021/JM1003667 )
  • 3L14: human carbonic anhydrase ii complexed with althiazide
  • 3M04: carbonic anhydrase ii in complex with novel sulfonamide inhibitor
  • 3M14: carbonic anhydrase ii in complex with novel sulfonamide inhibitor
  • 3M1J: the crystal structure of a nami a-carbonic anhydrase ii adduct discloses the mode of action of this novel anticancer metallodrug (10.1002/CMDC.201000331 )
  • 3M1K: carbonic anhydrase in complex with fragment (10.1002/CMDC.201000200 )
  • 3M1Q: carbonic anhydrase ii mutant w5c-h64c with opened disulfide bond
  • 3M1W: carbonic anhyrdase ii mutant w5ch64c with closed disulfide bond in complex with sulfate
  • 3M2N: crystal structure of human carbonic anhydrase isozyme ii with 4-{2-[n- (6-chloro-5-nitropyrimidin-4-yl)amino]ethyl}benzenesulfonamide (10.1016/J.EJMECH.2012.02.050 )
  • 3M2X: carbonic anhydrase ii in complex with novel sulfonamide inhibitor
  • 3M2Y: carbonic anhydrase ii in complex with novel sulfonamide inhibitor
  • 3M2Z: fragment tethered to carbonic anhydrase ii h64c mutant
  • 3M3X: crystal structure of human carbonic anhydrase isozyme ii with 4-{2-[n- (6-methoxy-5-nitropyrimidin-4-yl)amino]ethyl}benzenesulfonamide (10.1016/J.BMC.2010.09.011 )
  • 3M40: crystal structure of human carbonic anhydrase isozyme ii with 4-[n-(6- chloro-5-nitropyrimidin-4-yl)amino]benzenesulfonamide (10.1016/J.BMC.2010.09.011 )
  • 3M5E: crystal structure of human carbonic anhydrase isozyme ii with 4-{[n- (6-chloro-5-formyl-2-methylthiopyrimidin-4-yl) amino]methyl}benzenesulfonamide (10.1016/J.BMC.2010.09.011 )
  • 3M5S: carbonic anhydrase ii mutant h64c in complex with carbonate
  • 3M5T: fragment tethered to carbonic anhydrase ii h64c mutant
  • 3M67: crystal structure of human carbonic anhydrase isozyme ii with 2- chloro-5-[(6,7-dihydro-1h-[1,4]dioxino[2,3-f]benzimidazol-2- ylsulfanyl)acetyl]benzenesulfonamide (10.1016/J.BMC.2010.09.016 )
  • 3M96: crystal structure of human carbonic anhydrase isozyme ii with 5-{[(5- bromo-1h-benzimidazol-2-yl)sulfanyl]acetyl}-2- chlorobenzenesulfonamide (10.1016/J.BMC.2010.09.016 )
  • 3M98: crystal structure of human carbonic anhydrase isozyme ii with 5-(1h- benzimidazol-1-ylacetyl)-2-chlorobenzenesulfonamide
  • 3MHC: crystal structure of human cabonic anhydrase ii in adduct with an adamantyl analogue of acetazolamide in a novel hydrophobic binding pocket (10.1016/J.BMCL.2010.06.082 )
  • 3MHI: crystal structure of human carbonic anhydrase isozyme ii with 4-{[(5- nitro-6-oxo-1,6-dihydro-4-pyrimidinyl)amino]methyl}benzenesulfonamide (10.1016/J.BMC.2010.09.011 )
  • 3MHL: crystal structure of human carbonic anhydrase isozyme ii with 4-{[n- (6-methoxy-5-nitropyrimidin-4-yl)amino]methyl}benzenesulfonamide (10.1016/J.BMC.2010.09.011 )
  • 3MHM: crystal structure of human carbonic anhydrase isozyme ii with 4-{[n- (6-benzylamino-5-nitropyrimidin-4-yl)amino]methyl}benzenesulfonamide (10.1016/J.BMC.2010.09.011 )
  • 3MHO: crystal structure of human carbonic anhydrase isozyme ii with 4-[n-(6- chloro-5-formyl-2-methylthiopyrimidin-4-yl)amino]benzenesulfonamide (10.1016/J.BMC.2010.09.011 )
  • 3ML2: human carbonic anhydsase ii in complex with an aryl sulfonamide inhibitor (10.1016/J.BMC.2010.06.028 )
  • 3MMF: crystal structure of human carbonic anhydrase ii in complex with a 1, 3,5-triazine-substituted benzenesulfonamide inhibitor (10.1016/J.BMC.2011.04.005 )
  • 3MNA: the crystal structure of human carbonic anhydrase ii in complex with a 1,3,5-triazine-substituted benzenesulfonamide inhibitor (10.1016/J.BMC.2011.04.005 )
  • 3MNH: human carbonic anhydrase ii mutant k170a (10.1021/BI1007645 )
  • 3MNI: human carbonic anhydrase ii mutant k170d (10.1021/BI1007645 )
  • 3MNJ: human carbonic anhydrase ii mutant k170e (10.1021/BI1007645 )
  • 3MNK: human carbonic anhydrase ii mutant k170h (10.1021/BI1007645 )
  • 3MNU: carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron containing aromatic sulfamide with mammalian isoforms i-xv (10.1016/J.BMCL.2010.04.114 )
  • 3MWO: human carbonic anhydrase ii in a doubled monoclinic cell: a re- determination (10.1107/S0907444910023723 )
  • 3MYQ: crystal structure of human carbonic anhydrase isozyme ii with 2- chloro-5-[(1h-imidazo[4,5-c]quinolin-2-ylsulfanyl) acetyl]benzenesulfonamide (10.1016/J.BMC.2010.09.016 )
  • 3MZC: human carbonic ahydrase ii in complex with a benzenesulfonamide inhibitor (10.1039/C0CC02707C )
  • 3N0N: crystal structure of human carbonic anhydrase ii in complex with a benzenesulfonamide inhibitor (10.1039/C0CC02707C )